home / stock / nby / nby message board
Subject | By | Source | When |
---|---|---|---|
What do you make of this? | Trofee | investorshub | 06/20/2023 1:02:22 PM |
$NBY The trading | roberttatge | investorshub | 04/21/2023 9:26:29 AM |
$NBY best news of the day | roberttatge | investorshub | 04/20/2023 9:05:00 AM |
Price trading | Trofee | investorshub | 04/11/2023 5:56:29 PM |
$NBY short squeeze all day | Silver Paddy | investorshub | 04/08/2023 6:51:21 AM |
What's up with this stock. I am liking | Silver Paddy | investorshub | 07/15/2021 4:09:28 PM |
Is there any news, big news?? | Trofee | investorshub | 07/03/2019 5:39:01 PM |
]A battle is brewing just south of James | roberttatge | investorshub | 08/01/2017 5:09:37 PM |
NOTE TO MOOSE $CREE NATION, FACEBOK... | roberttatge | investorshub | 07/11/2017 1:20:26 PM |
REFER TO: | roberttatge | investorshub | 07/10/2017 8:51:56 PM |
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the...
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE...
Growth driven by efficient Avenova ® direct-to-consumer e-marketing programs NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase ...